Year: 2026
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, prevents antibody-mediated platelet destruction and has proven efficacy and safety in immune thrombocytopenia (ITP). However, evidence from real-world use in earlier treatment lines is limited. Here the objective was to evaluate the effectiveness and safety of fostamatinib as second- or third-line therapy in adult patients with ITP in Spain. METHODS: This multicenter study included 72 adult patients treated with fostamatinib across 22 Spanish centers, assessed retrospectively and prospectively. Demographic, clinical, and laboratory data, treatment responses, and adverse events (AEs) were analyzed. RESULTS: /L. Bleeding manifestations were present in 26.4% of patients. Overall, 83.3% achieved a response and 65.3% a complete response. Response rates were 76.0% with second-line and 87.2% with third-line fostamatinib, with complete response rates of 56.0% and 70.2%, respectively. The median time to platelet response was 10.5 days, and the median time to peak platelet count was 62 days. Forty patients (55.5%) received fostamatinib as monotherapy. AEs occurred in 44.4% of patients, were predominantly grade 1-2, and most commonly consisted of diarrhea and hypertension. Treatment discontinuation due to insufficient effectiveness occurred in 27.8% of patients. CONCLUSION: Fostamatinib demonstrated high effectiveness and acceptable tolerability as second- or third-line therapy for adult ITP in real-world clinical practice.
Source: Advances in Therapy
Authors: Tomás José González-López, Nuria Bermejo-Vega, Rocío Cardesa-Cabrera, Natalia Acedo, Josefa Luis-Navarro, Sunil Lakhwani, Silvia Bernat, Guillermo Enrique Haces-Tirado, Pilar Galán, María Luisa Lozano, Daniel Martínez-Carballeira, Roberto Hernández-Martin, Reyes Jimenez-Bárcenas, Begoña Navas-Elorza, Shally Marcellini, Ana Torres-Tienza, Alvaro Perona-Blázquez, Carmen Benet, Dolores Fernandez-Jimenez, Carolina López-Santamaría Castro, Isidro Jarque, Violeta Martínez, Isabel González-Gascón-y-Marín, Gloria García-Donás Gabaldón
Institutions: Hospital Universitario de Burgos, Complejo Hospitalario de Cáceres, Hospital Universitario de La Princesa, Hospital Riotinto, Universidad de La Laguna, Hospital Universitario de Canarias, Hospital Clínico Universitario Lozano Blesa, Hospital General De Segovia, Hospital General Universitario Morales Meseguer, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria, Universidad de Murcia, Hospital Universitario Central de Asturias, Hospital Virgen de la Concha, Hospital Clínico San Carlos, Complejo Hospitalario Universitario de Albacete, Hospital Arnau de Vilanova, Hospital Universitari i Politècnic La Fe, Complejo Asistencial Universitario de León, Hospital Universitario Infanta Leonor, Hospital Universitario Virgen Macarena
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,790
Funder: Grifols
OpenAlex ID: W7204875780